Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft-Tissue Sarcomas: <i>Post Hoc</i> Analysis of a Prospective Randomized Trial (SARC021/TH CR-406)

CIV was not associated with superior outcomes over BOL within DOX dosing limits of SARC021. Cardiac AEs were associated with increasing cumulative DOX dose. While not randomized with respect to DOX delivery mode, the results indicate that continued investigation of AE mitigation strategies is warranted.